Literature DB >> 14766884

Comparison of two microdilution methods for testing susceptibility of Candida spp. to voriconazole.

Maria José Linares1, Guadalupe Charriel, Francisco Solís, Manuel Casal.   

Abstract

The growing number of fungal infections, coupled with emerging resistance to classical antifungal agents, has led to the development of new agents, among them voriconazole. Susceptibility to voriconazole was tested by using two microdilution techniques: the reference method described in National Committee for Clinical Laboratory Standards document M27-A2 and a colorimetric method, Sensititre YeastOne. A total of 272 Candida isolates (132 of Candida albicans, 62 of C. parapsilosis, 33 of Candida glabrata, 21 of C. krusei, 15 of C. tropicalis, and 9 of C. lusitaniae) and two control strains (C. parapsilosis ATCC 22019 and C. krusei ATCC 6258) were tested. There was a high rate of agreement between the two methods used (97 to 100%).

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14766884      PMCID： PMC344459          DOI： 10.1128/JCM.42.2.899-902.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  18 in total

Review 1.  In vitro antifungal susceptibility methods and clinical implications of antifungal resistance.

Authors:  A Espinel-Ingroff; D W Warnock; J A Vazquez; B A Arthington-Skaggs
Journal:  Med Mycol       Date:  2000       Impact factor: 4.076

Review 2.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

4.  Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates.

Authors:  M A Pfaller; Q Vu; M Lancaster; A Espinel-Ingroff; A Fothergill; C Grant; M R McGinnis; L Pasarell; M G Rinaldi; L Steele-Moore
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

5.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients.

Authors:  D J Hoban; G G Zhanel; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

7.  In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.

Authors:  F Marco; M A Pfaller; S Messer; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

8.  In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

9.  Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.

Authors:  A Espinel-Ingroff; M Pfaller; S A Messer; C C Knapp; S Killian; H A Norris; M A Ghannoum
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species.

Authors:  G Morace; G Amato; F Bistoni; G Fadda; P Marone; M T Montagna; S Oliveri; L Polonelli; R Rigoli; I Mancuso; S La Face; L Masucci; L Romano; C Napoli; D Tatò; M G Buscema; C M C Belli; M M Piccirillo; S Conti; S Covan; F Fanti; C Cavanna; F D'Alò; L Pitzurra
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948
View more
  5 in total

1.  Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates.

Authors:  Dilek Yesim Metin; Suleyha Hilmioglu-Polat; Pinar Samlioglu; Biray Doganay-Oflazoglu; Ramazan Inci; Emel Tumbay
Journal:  Mycopathologia       Date:  2011-03-20       Impact factor: 2.574

2.  Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods.

Authors:  Maria José Linares; Guadalupe Charriel; Francisco Solís; Fernando Rodriguez; Ana Ibarra; M Casal
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

3.  In vitro activity of voriconazole against Prototheca wickerhamii: comparative evaluation of sensititre and NCCLS M27-A2 methods of detection.

Authors:  Maria José Linares; Francisco Solís; Manuel Casal
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

4.  Comparison of Two Commercial Colorimetric Broth Microdilution Tests for Candida Susceptibility Testing: Sensititre YeastOne versus MICRONAUT-AM.

Authors:  Sophie Philips; Frederik Van Hoecke; Emmanuel De Laere; Steven Vervaeke; Roos De Smedt; Jerina Boelens; Deborah De Geyter; Denis Piérard; Katrien Lagrou
Journal:  J Fungi (Basel)       Date:  2021-05-01

5.  Voriconazole in the management of nosocomial invasive fungal infections.

Authors:  Javier Pemán; Miguel Salavert; Emilia Cantón; Isidro Jarque; Eva Romá; Rafael Zaragoza; Angel Viudes; Miguel Gobernado
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.